{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:36:49Z","timestamp":1791988609213,"version":"4.4.0"},"reference-count":25,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2018,1,20]]},"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>We explored the relationships between programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression and the pathological and clinical features of thymic epithelial tumours and thymic hyperplasia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We evaluated PD-1 and PDL-1 expressions within epithelial and microenvironmental components in thymic epithelial tumours (n=44) and thymic hyperplasias (n=8), immunohistochemically. We compared the results with demographic, clinical and histopathological features of the cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found 48% epithelial expression and 82.7% microenvironment expression for PD-1 and 11.5% epithelial expression and 34.6% microenvironment expression for PD-L1. There was no PD-1 expression, in either the epithelial or microenvironment, in the thymic hyperplasia group. PD-1 and PD-L1 positivity was more significant in thymic epithelial tumours than thymic hyperplasia. Patients with PD-1-positive microenvironments exhibited significantly shorter mean estimated survival time than their negative counterparts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings suggest that anti-PD-1 and anti-PD-L1 therapies may benefit patients due to high release of PD-1 and PD-L1 in thymic epithelial tumours.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jclinpath-2017-204788","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T12:15:23Z","timestamp":1518092123000},"page":"637-641","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus"],"prefix":"10.1136","volume":"71","author":[{"given":"Emine Kilic","family":"Bagir","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arbil","family":"Acikalin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Avci","sequence":"additional","affiliation":[{"name":"Department of Chest Surgery, Faculty of Medicine, Cukurova University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Gumurdulu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Paydas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"2025092510385038000_71.7.637.1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.348"},{"key":"2025092510385038000_71.7.637.2","doi-asserted-by":"crossref","first-page":"56233","DOI":"10.18632\/oncotarget.9316","article-title":"Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer","volume":"7","author":"Zheng","year":"2016","journal-title":"Oncotarget"},{"key":"2025092510385038000_71.7.637.3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12032-016-0807-z","article-title":"Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas","volume":"33","author":"Paydas","year":"2016","journal-title":"Med Oncol"},{"key":"2025092510385038000_71.7.637.4","doi-asserted-by":"crossref","first-page":"30772","DOI":"10.18632\/oncotarget.8956","article-title":"Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"2025092510385038000_71.7.637.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2015.10.044"},{"key":"2025092510385038000_71.7.637.6","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.5858\/132.12.1859.a","article-title":"Evidence-based pathology and the pathologic evaluation of thymomas","volume":"132","author":"Rosai","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"2025092510385038000_71.7.637.7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23492"},{"key":"2025092510385038000_71.7.637.8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.21037\/jtd.2016.03.24","article-title":"Clinicopathological analysis of 241 thymic epithelial tumors\u2014experience in the Shanghai Chest Hospital from 1997\u20132004","volume":"8","author":"Zhu","year":"2016","journal-title":"J Thorac Dis"},{"key":"2025092510385038000_71.7.637.9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"2025092510385038000_71.7.637.10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"key":"2025092510385038000_71.7.637.11","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000429"},{"key":"2025092510385038000_71.7.637.12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.5.891"},{"key":"2025092510385038000_71.7.637.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2403-2"},{"key":"2025092510385038000_71.7.637.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.02.009"},{"key":"2025092510385038000_71.7.637.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2025092510385038000_71.7.637.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.003"},{"key":"2025092510385038000_71.7.637.17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"key":"2025092510385038000_71.7.637.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0434"},{"key":"2025092510385038000_71.7.637.19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy","volume":"99","author":"Katsuya","year":"2016","journal-title":"Lung Cancer"},{"key":"2025092510385038000_71.7.637.20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0034"},{"key":"2025092510385038000_71.7.637.21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003689"},{"key":"2025092510385038000_71.7.637.22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5858\/134.3.341","article-title":"Protocol for the examination of specimens from patients with merkel cell carcinoma of the skin","volume":"134","author":"Rao","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"2025092510385038000_71.7.637.23","first-page":"39001-39011","article-title":"Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"key":"2025092510385038000_71.7.637.24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.555"},{"key":"2025092510385038000_71.7.637.25","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/404069"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2017-204788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:39:00Z","timestamp":1758821940000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2017-204788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,18]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/jclinpath-2017-204788"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2017-204788","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]}}}